{"nctId":"NCT01084005","briefTitle":"Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes","startDateStruct":{"date":"2010-03"},"conditions":["Diabetes Mellitus, Type 2"],"count":241,"armGroups":[{"label":"linagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: linagliptin"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"linagliptin","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Type 2 diabetes mellitus\n2. HbA1c \\>= 7.0%\n3. Age \\>= 70 years\n4. Signed and dated written informed consent\n\nExclusion criteria:\n\n1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent\n2. Impaired hepatic function\n3. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors or rapid acting or pre-mixed insulins\n4. Treatment with anti-obesity drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline to Week 24","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.07"},{"groupId":"OG001","value":"-0.61","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline to Week 6","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.05"},{"groupId":"OG001","value":"-0.42","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline to Week 12","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.06"},{"groupId":"OG001","value":"-0.60","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline to Week 18","description":"HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.07"},{"groupId":"OG001","value":"-0.58","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline to Week 24","description":"This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"4.3"},{"groupId":"OG001","value":"-10.6","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline to Week 6","description":"This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"2.7"},{"groupId":"OG001","value":"-14.1","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline to Week 12","description":"This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"2.9"},{"groupId":"OG001","value":"-14.7","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline to Week 18","description":"This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"3.6"},{"groupId":"OG001","value":"-12.0","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7.0% at Week 24","description":"The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%. Only patients with baseline HbA1c \\>= 7%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"38.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7.0% at Week 24","description":"The percentage of patients with an HbA1c value below 7% at week 24 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"41.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5% at Week 24","description":"The percentage of patients with an HbA1c reduction of â‰¥0.5% at week 24 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"54.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Rescue Therapy","description":"The use of rescue therapy was planned for patients failing to achieve preset criteria based on glucose levels during the randomised treatment period of the trial","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":79},"commonTop":["Hypoglycaemia","Nasopharyngitis","Hyperglycaemia","Urinary tract infection","Diarrhoea"]}}}